All In Biotech

Drug Trial Radar · NCT07105215

A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors

A Multicenter Phase I/II Clinical Study to Evaluate the Safety and Efficacy of RC278 for Injection in the Treatment of Locally Advanced Unresectable or Metastatic Malignant Solid Tumor

Last checked: Nov 19, 2026Latest source record: Nov 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

312

Planned (sponsor's estimate)

Start

Aug 11, 2025

Primary completion

Dec 31, 2027

Study completion May 31, 2030

Sponsor

Lead sponsor
RemeGen Co., Ltd.Industry
Sponsor type
Industry
First posted
Aug 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to evaluate the safety and tolerability of RC278; determine the maximum tolerated dose (MTD) and/or maximum administered dose (MAD) of RC278; and determine the recommended phase 2 dose (RP2D), and assess the efficacy of RC278 at the RP2D dose;

Conditions

  • Solid Tumors

Interventions

  • RC278Drug

    Intravenous (IV) administration of RC278 Q3W. Patients will continue treatment until unacceptable toxicities, disease progression, or any criterion for withdrawl from the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-Limiting Toxicity (DLT)Time frame: 24 months
  2. Incidence and severity of adverse events/serious adverse events (graded according to NCI CTCAE v5.0)Time frame: 24 months
  3. Determine RP2D of RC278Time frame: 24 months
  4. MTD and/or MADTime frame: 24 months
  5. Investigator assessed ORR according to RECIST v1.1 criteriaTime frame: 24 months

Locations

39 sites in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangzhou, China · Recruiting

  • The First Affiliated Hospital, Zhejiang University School Of Medicine

    Hangzhou, China · Recruiting

  • Cancer Hospital of Shandong First Medical University

    Jinan, China · Recruiting

  • Jinan Central Hospital

    Jinan, China · Recruiting

  • Shanxi Cancer Hospital

    Taiyuan, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, China · Recruiting

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Recruiting

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Recruiting

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China · Recruiting

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China · Recruiting

  • The Second Affiliated Hospital of Guilin Medical University

    Guilin, Guangxi, China · Recruiting

  • Guangxi Medical University Cancer Hospital & Guangxi Cancer Institute

    Nanning, Guangxi, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Recruiting

  • Anyang Cancer Hospital

    Luoyan, Henan, China · Recruiting

  • The First Affiliated Hospital of Henan University of Science &Technology

    Luoyang, Henan, China · Recruiting

  • Nanyang Second General Hospital

    Nanyang, Henan, China · Recruiting

  • The First Affiliated Hospital of Xinxiang Medical University

    Xinxiang, Henan, China · Recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Recruiting

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China

    Wuhan, Hu'Nan, China · Recruiting

  • Hubei Cancer Hospital

    Wuhan, Hubei, China · Recruiting

  • Tongji Hospital, Tongji Medical College of HUST, China

    Wuhan, Hubei, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Recruiting

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China · Recruiting

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China · Recruiting

  • Xuzhou Central Hospital

    Xuzhou, Jiangsu, China · Recruiting

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China · Recruiting

  • Liaoning Cancer Hospital & Institute

    Shenyang, Liaoning, China · Recruiting

  • The first Hospital of China Medical University

    Shenyang, Liaoning, China · Recruiting

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

  • Zhongshan Hospital, Fudan University

    Shanghai, Shanghai Municipality, China · Recruiting

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China · Recruiting

  • Yunnan Tumor Hospital

    Kunming, Yunnan, China · Recruiting

  • Sir Run Run Shaw Hospital, affiliated with Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China · Recruiting

  • Taizhou Hospital of Zhejiang Province

    Taizhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.